X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Lupkynis (voclosporin) is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action. It is being developed for the treatment of lupus nephritis.
Lead Product(s): Voclosporin
Therapeutic Area: Nephrology Product Name: Lupkynis
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
Lupkynis (voclosporin) is an an oral calcineurin inhibitor which is being evaluated in clinical trials for the treatment of patients with Lupus Nephritis.
Lead Product(s): Voclosporin
Therapeutic Area: Nephrology Product Name: Lupkynis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
Lupkynis (voclosporin) is a calcineurin-inhibitor of calcineurin. The immunosuppressant activity results in inhibition of lymphocyte proliferation, T-cell cytokine production, and expression of T-cell activation surface antigens. Currently being developed for lupus nephritis.
Lead Product(s): Voclosporin
Therapeutic Area: Nephrology Product Name: Lupkynis
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
Lupkynis (voclosporin) is a novel, structurally modified calcineurin inhibitor (CNI) with dual mechanism of action, has received swissmedic approval to treat adults with active class III, IV and V lupus nephritis.
Lead Product(s): Voclosporin
Therapeutic Area: Immunology Product Name: Lupkynis
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
Lupkynis (voclosporin) is a calcineurin-inhibitor of calcineurin. The immunosuppressant activity results in inhibition of lymphocyte proliferation, T-cell cytokine production, and expression of T-cell activation surface antigens. Currently being developed for lupus nephritis.
Lead Product(s): Voclosporin,Mycophenolate Mofetil,Undisclosed
Therapeutic Area: Nephrology Product Name: Lupkynis
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
Details:
Lupkynis (voclosporin) is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney.
Lead Product(s): Voclosporin
Therapeutic Area: Nephrology Product Name: Lupkynis
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
Lupkynis (voclosporin) is a calcineurin-inhibitor of calcineurin. The immunosuppressant activity results in inhibition of lymphocyte proliferation, T-cell cytokine production, and expression of T-cell activation surface antigens. Currently being developed for lupus nephritis.
Lead Product(s): Voclosporin,Mycophenolate Mofetil,Undisclosed
Therapeutic Area: Nephrology Product Name: Lupkynis
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
Lupkynis (voclosporin) is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney.
Lead Product(s): Voclosporin
Therapeutic Area: Nephrology Product Name: Lupkynis
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
LUPKYNIS (voclosporin) is novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney.
Lead Product(s): Voclosporin
Therapeutic Area: Nephrology Product Name: Lupkynis
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
AUR200 is a recombinant Fc fusion protein designed to specifically BAFF and APRIL. BAFF and APRIL promote B cell survival and differentiation and have been shown to play a prominent role in the pathogenesis of certain autoimmune and nephrology conditions.
Lead Product(s): AUR200
Therapeutic Area: Immunology Product Name: AUR200
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
